Purchase Order 75N91019P00115

<p>The National Cancer Institute awarded a purchase order to Gryphon Scientific, LLC for $63,300 on September 23, 2019, to identify radiation-injury markers predicting organ damage and survival following whole-body irradiation in mouse and minipig models. Work is performed in Beverly, Massachusetts under a firm fixed-price structure, with completion targeted for November 22, 2019. The order originated from a Special Notice posted August 19, 2019 with a due date of August 26, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genus Biosystems Inc. valued at $57,268.80 on August 3, 2018, to test radiation-induced mRNAs in a mini pig model and determine whether these mRNAs can be used as organ-specific markers at various doses and time points. No set-aside applied. Work is performed in Northbrook, Illinois. The order is firm fixed price with an ultimate completion date of August 2, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Gryphon Scientific, LLC for $13,340.00 on December 1, 2017, with an ultimate completion date of November 30, 2018. No set-aside was used. Performance will take place in Bethesda, Maryland. The order is priced as fixed price with economic price adjustment. Specific requirements are not detailed in the source.</p>

<p>The National Cancer Institute awarded a purchase order to Gryphon Scientific, LLC for $9,895.00 with a firm fixed price on July 26, 2017, with ultimate completion by August 28, 2017. No set-aside category was used. Place of performance is Beverly, Massachusetts. The source does not specify the procured items or services.</p>

<p>The National Cancer Institute awarded a purchase order to Gryphon Scientific, LLC valued at $38,200 for radiation inducible molecular targets identification after single and fractionated radiation in prostate carcinoma, with an award date of April 9, 2018 and ultimate completion date of April 9, 2019. Work is performed in Brookline, New Hampshire under firm fixed price terms with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Biocytogen LLC for $10,000.00 on April 3, 2018. Work is performed in Worcester, Massachusetts. The order carries a firm fixed price for commercial items, with ultimate completion on May 3, 2018. No small business set-aside was applied.</p>

<p>The National Cancer Institute awarded a purchase order to Noldus Information Technology, Inc. for $14,797.00 on September 8, 2017, with ultimate completion on September 7, 2018. Performance occurs in Bethesda, Maryland. The order is fixed-price with economic price adjustment and carries no small business set-aside. The source does not specify the particular equipment, software, or services procured under this order.</p>

<p>The National Cancer Institute awarded a purchase order to Government Scientific Source Inc., a small business, for $24,591.00 on April 21, 2021. The order covers Chromium Next GEM chip G single cell and other materials. Place of performance is Reston, Virginia. The order carries a firm fixed price and an ultimate completion date of May 31, 2021.</p>

<p>The National Cancer Institute awarded a purchase order to Global Life Sciences Solutions USA LLC for $11,440 on March 8, 2018, with completion by March 27, 2019. Work is performed in Bethesda, Maryland. The order is firm fixed price with no set-aside applied. Specific scope of supply is not detailed in the award record.</p>

<p>The National Cancer Institute issued a purchase order to Taconic Biosciences, Inc. for $15,688.00, awarded September 10, 2020, with completion by February 9, 2021. The order procures animal research and production services, with place of performance in Rensselaer, New York. Pricing is firm fixed price on a simplified acquisition with no small business set-aside.</p>